Last reviewed · How we verify
Human Recombinant Regular Insulin infusion — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Human Recombinant Regular Insulin infusion (Human Recombinant Regular Insulin infusion) — Wanpen Vongpatanasin.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Human Recombinant Regular Insulin infusion TARGET | Human Recombinant Regular Insulin infusion | Wanpen Vongpatanasin | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Human Recombinant Regular Insulin infusion CI watch — RSS
- Human Recombinant Regular Insulin infusion CI watch — Atom
- Human Recombinant Regular Insulin infusion CI watch — JSON
- Human Recombinant Regular Insulin infusion alone — RSS
Cite this brief
Drug Landscape (2026). Human Recombinant Regular Insulin infusion — Competitive Intelligence Brief. https://druglandscape.com/ci/human-recombinant-regular-insulin-infusion. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab